If you are an American investor who is confused about what to look for next week, Jim Cramer would turn out to be your best friend, philosopher and guide, especially after the number of recommendations which he made on CNBC on Friday, 5th December, 2014. Amongst the several stocks which he mentioned on a day-to-day…
Agios Pharma Soaring 27% Pre-Bell; AG-221 Demonstrates Clinical Acitivity in Blood Cancer Patients
Agios Pharmaceuticals (AGIO) shares were up 27% in recent pre-market trade after saying this weekend that data from a study on the AG-221 drug in patients with advanced blood cancers showed “promising” clinical activity. AGIO is in the upper half of the 52-week range between $15.77 and $49.79. The purpose of the phase 1 program…